Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

← Paediatrics and child health indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Genetic counselling and recurrence risk

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Purpose and principles

Deliver non-directive genomic counselling, calculate and communicate recurrence risk from diagnosis and inheritance, explain uncertainty and reproductive options, support family communication and document an agreed plan across life stages.

Genetic counselling helps a person or family understand a diagnosis, adapt to its implications and make decisions consistent with their own values. A good consultation is reciprocal. Ask what prompted the appointment, what the family already believes, whether there is guilt or blame, who should be present and what outcome would be useful today. Use a professional interpreter rather than a child or relative when language support is required. Explain specialist terms in ordinary words, invite teach-back and accept that several conversations may be needed before reproductive decisions.

Risk calculation starts with evidence quality. Review the original laboratory report, clinical criteria, phenotype and three-generation pedigree. Confirm whether a variant is pathogenic, likely pathogenic or uncertain; whether disease is autosomal dominant, recessive, X-linked, mitochondrial, chromosomal or multifactorial; whether parental samples establish de novo status; and whether penetrance or sex limitation applies. Do not quote a familiar fraction when the familial diagnosis is unverified. A one-in-two transmission chance for an autosomal dominant variant may coexist with a lower or age-dependent disease chance.

Autosomal recessive counselling distinguishes an affected person, a carrier and population carrier probability. Two confirmed carriers of pathogenic variants in the same gene usually face a one-in-four chance of an affected child, one-in-two chance of a carrier and one-in-four chance of a child inheriting neither familial variant in each pregnancy. If variants have different severity, reduced penetrance or uncertain phase, specialist interpretation modifies that simple model. Testing a partner begins with ancestry-independent clinical criteria and the familial mechanism, not with assumptions based on ethnicity alone.

X-linked counselling depends on the exact disorder and parental sex. A heterozygous woman may pass the altered X chromosome to half of children, while expression in daughters can vary. An affected male passes his X chromosome to all daughters and no sons. Mitochondrial DNA is transmitted through the ovum, but heteroplasmy and bottleneck effects can make recurrence and severity hard to predict. Chromosome rearrangements require the specific parental karyotype because gamete imbalance risk varies by chromosomes, breakpoints, sex and ascertainment.

De novo does not mean zero recurrence. When a child's pathogenic variant is absent from both parental blood samples and parentage is confirmed, recurrence is often low, but a parent may have germline or low-level somatic mosaicism undetected in blood. Conversely, a clinically unaffected parent can carry a variant with reduced penetrance or subtle expression. Discuss the best evidence-based residual estimate and whether targeted prenatal or preimplantation testing remains technically possible rather than giving false reassurance or implying that another affected child is likely.

Reproductive options are time-sensitive and preference-sensitive. Natural conception without testing is a valid choice. Chorionic villus sampling and amniocentesis provide diagnostic fetal material but carry procedural and timing implications; non-invasive prenatal testing is not a diagnostic test for most single-gene family conditions. Preimplantation genetic testing requires IVF, an approved or eligible condition and a family-specific test and may not produce a transferable unaffected embryo. Donor gametes, donor embryos, adoption and not pursuing parenthood may be considered, while access and funding vary.

Testing children raises best-interest questions. Diagnostic testing can guide present care. Predictive testing for a serious childhood-onset, medically actionable condition may offer surveillance benefit. Testing solely for an adult-onset disorder with no childhood action is often deferred so the future adult can decide, although every situation requires individual assessment. Involve the child according to understanding, respect a competent young person's decision and plan how results will be disclosed over time rather than leaving parents to carry a permanent secret.

Family information is shared but not ownerless. The patient normally decides how to tell relatives. Provide a de-identified family letter that states the condition, relevance and referral route without unnecessary personal history. If refusal to share exposes an identifiable relative to serious preventable harm, seek consent again, explore reasons, discuss with senior genetics and information-governance colleagues and apply GMC confidentiality principles. Any disclosure without consent must be exceptional, proportionate, limited and documented.

Follow-up should convert discussion into action. Identify which laboratory or referral forms are needed, who contacts obstetrics or fertility services, what gestational or age deadlines apply and when results will be reviewed. Offer psychological support for grief, guilt, uncertainty or family conflict without pathologising a difficult decision. Revisit counselling when classifications change, new relatives are diagnosed, pregnancy is planned, a young person matures or genomic technology creates a genuinely new option.

Key points

  • Begin with the person's question, values, language, family structure and current understanding; genetic counselling is a communication and decision process rather than a laboratory result recital.
  • Confirm the exact diagnosis, gene or chromosome finding, inheritance, penetrance, variant classification and whether parental or segregation testing is complete before quoting recurrence figures.
  • Separate chance of inheriting a variant from chance of developing disease and expected severity; penetrance, sex, mosaicism and variable expression can make these different.
  • Mendelian probabilities apply independently to each conception: previous outcomes do not make the next pregnancy due for an affected or unaffected result.
  • A negative parental blood test after an apparently de novo diagnosis usually lowers recurrence substantially but cannot remove germline mosaicism or an unexpected biological relationship from consideration.
  • Present pregnancy without testing, prenatal diagnosis, preimplantation genetic testing where eligible, donor conception, adoption and choosing not to have children as options without ranking moral worth.
  • Discuss who in the wider family may benefit and support patient-led communication with a genetics letter; do not assume permission to contact relatives directly.

Indications, selection and cautions

Diagnostic counselling need

A new genomic result changes explanation, prognosis, surveillance or family risk and requires supported interpretation beyond report delivery.

Pre-test decision need

Testing could create uncertain, predictive, reproductive or familial information that a person should consider before sampling.

Reproductive time pressure

Current pregnancy, fertility decline or planned conception creates deadlines for laboratory work-up, prenatal diagnosis or fertility referral.

Family communication barrier

Estrangement, guilt, safety concerns, language barriers or disagreement can prevent relevant information reaching at-risk relatives.

Uncertain risk

Mosaicism, reduced penetrance, an uncertain variant or incomplete parental testing makes a simple Mendelian fraction misleading.

Assessment before treatment

  1. 01
    Original genomic reportFirst step
    Why
    Verify the gene, variant, transcript, classification, assay and laboratory interpretation.
    Interpretation and limitations
    Counselling based on an abbreviated family account can confuse uncertain and pathogenic findings or the wrong relative.
  2. 02
    Three-generation pedigree
    Why
    Map phenotype, transmission clues, reproductive outcomes and relatives who may benefit.
    Interpretation and limitations
    Reported diagnoses need verification, and small families or age-dependent disease can conceal an inheritance pattern.
  3. 03
    Parental or segregation testing
    Why
    Clarify inheritance, de novo status, phase and informative family branches.
    Interpretation and limitations
    A negative blood result can lower risk but may not exclude germline or tissue-limited parental mosaicism.
  4. 04
    Carrier or partner testing
    Why
    Refine reproductive risk for recessive or selected sex-linked conditions.
    Interpretation and limitations
    Residual risk remains after a negative test because coverage and variant detection are never absolute.
  5. 05
    Prenatal diagnostic testing
    Why
    Test a pregnancy for a known familial condition using placental or amniotic material.

Treatment approach

01PrepareVerify before estimatingFirst stepA person asks about their own or a relative's genomic recurrence risk.+
  1. 1Obtain the original report, relevant phenotype records and a dated three-generation pedigree.
  2. 2Confirm diagnosis, inheritance, penetrance, parental testing and any unresolved variant classification.
  3. 3Identify the person's immediate question, values, language needs and reproductive timeline.
02ExplainBuild risk in layersThe evidence is sufficient for a recurrence discussion.+
  1. 1State the baseline inheritance model using absolute frequencies and an understandable denominator.
  2. 2Separate variant transmission, disease penetrance, severity uncertainty and test detection limitations.
  3. 3Use teach-back and written figures, making every assumption and residual risk explicit.

Complications, monitoring and follow-up

  • Check that requested parental, carrier or confirmatory tests were completed and that results were interpreted together rather than in isolation.
  • Record pregnancy or fertility deadlines and confirm that referrals reached services early enough to preserve genuine options.
  • Revisit understanding after written information because numerical recall and emotional processing change after the appointment.
  • Update recurrence advice when a variant is reclassified, mosaicism is identified or a relative's verified diagnosis changes the model.
  • Confirm that children with predictive results have an age-appropriate disclosure plan and active surveillance owner.
  • Review family communication outcomes without pressuring the patient to disclose more personal information than relatives need.

Special situations

One half has layers

A fifty-percent transmission probability is not necessarily a fifty-percent probability of symptoms when penetrance, sex or imprinting modifies expression.

De novo retains a remainder

Parental blood testing cannot completely exclude germline mosaicism, so recurrence often becomes low rather than mathematically zero.

Options are not recommendations

A clinician explains feasibility and consequences while the person decides which reproductive route, including no testing, fits their values.

The child will become an adult

Disclosure and predictive testing plans should protect present welfare while preparing future autonomy and direct access to the genomic record.

Family letters minimise disclosure

A carefully drafted genetics letter can convey the inherited risk and referral route without sharing the proband's wider clinical history.

Common pitfalls

  1. 01

    Quoting a Mendelian fraction before verifying the diagnosis and laboratory result.

  2. 02

    Confusing variant transmission with certainty of disease or severity.

  3. 03

    Telling parents that an apparently de novo result has zero recurrence risk.

  4. 04

    Presenting prenatal or preimplantation testing as the expected responsible choice.

  5. 05

    Testing a young child for adult-onset risk without considering present benefit.

  6. 06

    Contacting relatives directly before analysing consent and confidentiality.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Paediatrics and child healthOriginal SBA

Autosomal recessive recurrence

Two confirmed carriers of pathogenic variants causing the same autosomal recessive condition ask about each future pregnancy. Which explanation is most accurate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Paediatrics and child health topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS Genomics Education knowledge hubInheritance, penetrance, mosaicism, counselling and reproductive genomic concepts.
  • NHS England National Genomic Test DirectoryCurrent genomic testing pathways and eligibility that underpin accurate family testing.
  • GMC Decision making and consentNon-directive supported decisions, proportional information and capacity principles.
  • HFEA preimplantation genetic testingUK-regulated information about embryo testing, treatment steps, limitations and approved conditions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Record the numerical estimate, its assumptions, residual uncertainty, choices discussed, emotional response and who will arrange each test or referral.
Interpretation and limitations
Result scope, mosaicism, procedure timing and pregnancy choices require specialist fetal medicine and genetics counselling.
  • 06
    Preimplantation genetic testing work-up
    Why
    Determine technical feasibility and regulatory eligibility before IVF-based embryo testing.
    Interpretation and limitations
    Feasibility does not guarantee funding, ovarian response, unaffected embryos, implantation or live birth.
  • 03ChooseCompare reproductive routes neutrallyThe person wants to consider current or future conception options.+
    1. 1Describe natural conception, prenatal diagnosis, IVF with PGT, donor routes and no testing proportionately.
    2. 2Clarify timing, procedure, limitations, funding uncertainty and possible decisions after each result.
    3. 3Make the relevant genetics, fetal medicine or fertility referral without directing the final choice.
    04ShareSupport family communicationA result has potential health or reproductive relevance for relatives.+
    1. 1Ask whom the patient wants to inform and explore safety, estrangement or emotional barriers.
    2. 2Provide a concise family letter and route for relatives to seek their own confidential assessment.
    3. 3EscalationEscalate exceptional serious-harm dilemmas for senior ethical review before any disclosure without consent.